← Leaderboards
Jodi K Craigo
Cytoagents, Inc.
$3,661,822
Attributed
$3,661,822
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.8M · FY2020–22$2M$1.5M$1M$500K$0
'20
'21
'22
Funding mix
By agency
NIH$3,661,822 · 2
By mechanism
R44$3,661,822 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Investigational Drugs”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Beth Baseler · Leidos Biomedical Research, Inc.$83,440,795
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Timothy Fouts · Advanced Bioscience Laboratories, Inc.$42,497,655
- Gary Kobinger · University Of Texas Med Br Galveston$41,631,815
Research focus
Investigational DrugsInfluenzavirusHealthcare SystemsHealthcareImmunomodulatorsInfluenzaClinical PracticeDisease OutbreaksEconomic BurdenFunctional DisorderHospitalizationImmune ResponseAntiviral AgentsInfectionAntiviral TherapyAdaptive ImmunityCytokine Release SyndromeCytokineAcute Lung InjuryDoseEvaluationCaringCessation Of LifeLead
Grant awards (4)
Preclinical development of an immunomodulatory agent capable of mitigating SARS-CoV-2 virus related hypercytokinemia$1,000,000
R44 · FY2022 · AI · contact PI
Preclinical development of an immunomodulatory agent capable of mitigating SARS-CoV-2 virus related hypercytokinemia$1,000,000
R44 · FY2021 · AI · contact PI
Preclinical development of an immunomodulatory agent capable of mitigating influenza related hypercytokinemia$813,514
R44 · FY2021 · AI · contact PI
Preclinical development of an immunomodulatory agent capable of mitigating influenza related hypercytokinemia$848,308
R44 · FY2020 · AI · contact PI